FPOLayout for review — draft content, for placement only. Imagery and claims shown from global material pending Canadian adaptation. Ghosted items show the future full website.
PrFREHEMGO®denecimig injectionMy profileFPOENFR

Freedom* from bleeds for all**1

Discover powerful protection† at every stage of the hemophilia journey with once-monthly FREHEMGO®**1

FREHEMGO® halves bleed rates compared with FVIII PPx††2,3 — FRONTIER2 vs SoCFPO
0.3 mean ABR, 88% of paediatric patients had zero bleeds and 100% had target joint resolution‡‡5 — FRONTIER3 childrenFPO
0.7 mean ABR, 90% of patients had zero spontaneous bleeds and >70% had zero bleeds entirely‡4 — FRONTIER4 longer-termFPO

Shown as an efficacy summary — one or two headline results per study, per the approved summary slide. The FRONTIER4 FVIII-inhibitor sub-population is deliberately not featured: it is not in the Product Monograph.

Full website

Dedicated data page per study — Frontier 2, 3 and 4

The full website expands each card above into its own efficacy data page (per Aalia, 2026-08-12), with RWE to follow once studies are published. FPO

View more

TG chartFPO

Normal levels all month long

Learn how FREHEMGO® normalises thrombin generation all month long.

Discover the innovation
Patient imageryFPO

A proven safety profile

Ultra-potent protection without compromising on safety profile.

Explore safety data
Pen line-upFPO

Dosing made simple

No mg/kg dosing. No dose calculations — 5 prefilled pens.

Discover dosing